The combination of afatinib and cetuximab exerted a synergistic effect in EGFR TKI-resistant NSCLC from not only the inhibitory actions of multi-HER receptors but also from the dual inhibition of the extracellular and intracellular domains of EGFR85. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.